Founded in 2024 from the merger between Mipharm and Doppel, Domixtar Pharmaceutical S.p.A. (“DMX” and, together with its subsidiaries, the “Group”) is recognized as the Italian leader in the CDMO (Contract Development and Manufacturing Organization) sector. The Group specializes in developing integrated solutions for drug formulation and manufacturing, offering a comprehensive suite of technologies and liquid, solid, and semi-solid dosage forms with numerous applications. Its clients include some of the leading European and international pharmaceutical companies.

In March 2022, ACIV, through Kerix Partners, acquired control of Mipharm which, in turn, acquired Alfa Omega in February 2023 — a company specialized as a CDMO for supplements and homeopathic products. In September 2024, the merger between Mipharm and Doppel — a company active as a CDMO for pharmaceutical products and, to a lesser extent, food and medical products — was finalized, giving the Group its current structure.

In November 2025, Alto Capital IV and the other shareholders jointly sold 100% of DMX to a company controlled by Azzurra Capital and The Club Dealers.